These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
305 related articles for article (PubMed ID: 28842137)
21. Outcomes for transformed follicular lymphoma in the rituximab era: the Royal Marsden experience 2003-2013. Gleeson M; Hawkes EA; Peckitt C; Wotherspoon A; Attygalle A; Sharma B; Du Y; Ethell M; Potter M; Dearden C; Horwich A; Chau I; Cunningham D Leuk Lymphoma; 2017 Aug; 58(8):1805-1813. PubMed ID: 27931133 [TBL] [Abstract][Full Text] [Related]
22. The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study. Rossi D; Bruscaggin A; La Cava P; Galimberti S; Ciabatti E; Luminari S; Rigacci L; Tucci A; Pulsoni A; Bertoldero G; Vallisa D; Rusconi C; Spina M; Arcaini L; Angrilli F; Stelitano C; Merli F; Gaidano G; Federico M; Palumbo GA Haematologica; 2015 Apr; 100(4):517-24. PubMed ID: 25596266 [TBL] [Abstract][Full Text] [Related]
23. Chlorambucil-rituximab as first-line therapy in patients affected by follicular non-Hodgkin's lymphoma: a retrospective single-centre study. Martinelli G; Montoro J; Vanazzi A; Andreola G; Liptrott S; Radice D; Negri M; Preda L; Pruneri G; Laszlo D Hematol Oncol; 2015 Dec; 33(4):129-35. PubMed ID: 25047267 [TBL] [Abstract][Full Text] [Related]
24. Impact of prior treatment on outcome of transformed follicular lymphoma and relapsed de novo diffuse large B cell lymphoma: a retrospective multicentre analysis. Lerch K; Meyer AH; Stroux A; Hirt C; Keller U; Viardot A; Marks R; Schreiber S; Pezzutto A; Scholz CW Ann Hematol; 2015 Jun; 94(6):981-8. PubMed ID: 25645656 [TBL] [Abstract][Full Text] [Related]
25. Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy. Zucca E; Rondeau S; Vanazzi A; Østenstad B; Mey UJM; Rauch D; Wahlin BE; Hitz F; Hernberg M; Johansson AS; de Nully Brown P; Hagberg H; Ferreri AJM; Lohri A; Novak U; Zander T; Bersvendsen H; Bargetzi M; Mingrone W; Krasniqi F; Dirnhofer S; Hayoz S; Hawle H; Vilei SB; Ghielmini M; Kimby E; Blood; 2019 Jul; 134(4):353-362. PubMed ID: 31101627 [TBL] [Abstract][Full Text] [Related]
26. Rituximab maintenance improves outcomes of transformed diffuse large B-cell lymphoma: a retrospective study of 519 cases with Uryu H; Mishima Y; Tsuyama N; Yokoyama M; Nishimura N; Fukuta T; Shirouchi Y; Okabe T; Inoue N; Takeuchi K; Terui Y Leuk Lymphoma; 2021 Sep; 62(9):2141-2150. PubMed ID: 33749498 [TBL] [Abstract][Full Text] [Related]
27. Follicular non-Hodgkin's lymphoma: correlation between histology, pathophysiology, cytogenetic, prognostic factors, treatment, survival. Găman AM Rom J Morphol Embryol; 2013; 54(1):71-6. PubMed ID: 23529311 [TBL] [Abstract][Full Text] [Related]
28. Clinico-biological features, treatment and survival of 457 patients with histological Grades 3A and 1-2 follicular lymphoma mostly treated with immunochemotherapy. Mercadal S; Pomares H; Sancho JM; Climent F; García O; Encuentra M; Domingo-Doménech E; Sorigué M; Moreno M; Oliveira AC; Ribera JM; Fernández de Sevilla A; González-Barca E Br J Haematol; 2016 Feb; 172(3):470-3. PubMed ID: 26010479 [No Abstract] [Full Text] [Related]
29. The incidence of biopsy-proven transformation in follicular lymphoma in the rituximab era. A retrospective analysis from the Czech Lymphoma Study Group (CLSG) database. Janikova A; Bortlicek Z; Campr V; Kopalova N; Benesova K; Hamouzova M; Belada D; Prochazka V; Pytlik R; Vokurka S; Pirnos J; Duras J; Mocikova H; Mayer J; Trneny M Ann Hematol; 2018 Apr; 97(4):669-678. PubMed ID: 29318369 [TBL] [Abstract][Full Text] [Related]
31. Economic burden and treatment patterns for patients with diffuse large B-cell lymphoma and follicular lymphoma in the USA. Ren J; Asche CV; Shou Y; Galaznik A J Comp Eff Res; 2019 Apr; 8(6):393-402. PubMed ID: 30855175 [TBL] [Abstract][Full Text] [Related]
32. Subcutaneous rituximab in patients with diffuse large B cell lymphoma and follicular lymphoma: Final results of the non-interventional study MabSCale. Dürig J; Uhlig J; Gerhardt A; Ritter M; Hapke G; Heßling J; Staib P; Wolff F; Krumm K; von Weikersthal LF Cancer Med; 2023 Feb; 12(3):2739-2751. PubMed ID: 36017743 [TBL] [Abstract][Full Text] [Related]
33. Follicular lymphoma at relapse after rituximab containing regimens: comparison of time to event intervals prior to and after 90 Y-ibritumomab-tiuxetan. Cicone F; Russo E; Carpaneto A; Prior JO; Delaloye AB; Scopinaro F; Ketterer N Hematol Oncol; 2011 Sep; 29(3):131-8. PubMed ID: 20862654 [TBL] [Abstract][Full Text] [Related]
34. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. Herold M; Haas A; Srock S; Neser S; Al-Ali KH; Neubauer A; Dölken G; Naumann R; Knauf W; Freund M; Rohrberg R; Höffken K; Franke A; Ittel T; Kettner E; Haak U; Mey U; Klinkenstein C; Assmann M; von Grünhagen U; J Clin Oncol; 2007 May; 25(15):1986-92. PubMed ID: 17420513 [TBL] [Abstract][Full Text] [Related]
35. Outcomes of the transformation of follicular lymphoma to diffuse large B-cell lymphoma in the rituximab era: A population-based study. Zheng W; Liu M; Guan L; Wang S Cancer Med; 2024 Apr; 13(8):e7120. PubMed ID: 38629251 [TBL] [Abstract][Full Text] [Related]
36. Statin use is safe and does not impact prognosis in patient with de novo follicular lymphoma treated with immunochemotherapy: An exploratory analysis of the PRIMA cohort study. Bachy E; Estell JA; Van de Neste E; Bouabdallah R; Bargay J; Delmer A; Gelas-Dore B; Gomes da Silva M; Fitoussi O; Belada D; Maisonneuve H; Intragumtornchai T; Lamy T; Dartigues P; Seymour JF; Salles G Am J Hematol; 2016 Jun; 91(4):410-5. PubMed ID: 26799234 [TBL] [Abstract][Full Text] [Related]
37. Fludarabine, cyclophosphamide and rituximab as first-line treatment in patients with newly diagnosed follicular lymphoma. De la Cruz Vicente F; Carrillo-Cruz E; Rodriguez MS; Marín Niebla A; Galiana ML; Gonzalez JF; Cuadrado IM; Campos JG; Tocino IE; Rios-Herranz E; Perez-Simón JA Eur J Haematol; 2014 Dec; 93(6):469-75. PubMed ID: 24853381 [TBL] [Abstract][Full Text] [Related]
38. Prediction of high risk for death in patients with follicular lymphoma receiving rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in first-line chemotherapy. Murakami S; Kato H; Higuchi Y; Yamamoto K; Yamamoto H; Saito T; Taji H; Yatabe Y; Nakamura S; Kinoshita T Ann Hematol; 2016 Aug; 95(8):1259-69. PubMed ID: 27220639 [TBL] [Abstract][Full Text] [Related]
39. Clinicobiological features and prognostic impact of diffuse large B-cell lymphoma component in the outcome of patients with previously untreated follicular lymphoma. Magnano L; Balagué O; Dlouhy I; Rovira J; Karube K; Pinyol M; Rivas-Delgado A; Costa D; Martínez-Trillos A; González-Farre B; Martínez-Pozo A; Giné E; Colomer D; Delgado J; Villamor N; Campo E; López-Guillermo A Ann Oncol; 2017 Nov; 28(11):2799-2805. PubMed ID: 29045517 [TBL] [Abstract][Full Text] [Related]
40. [Comparison between CHOP-like and R-CHOP in diffuse large B cell and follicular lymphoma]. Oliver C; Guillermo C; Martínez P; Díaz L Rev Med Chil; 2013 Jul; 141(7):844-52. PubMed ID: 24356732 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]